Search

Your search keyword '"Spertini, F."' showing total 479 results

Search Constraints

Start Over You searched for: Author "Spertini, F." Remove constraint Author: "Spertini, F."
479 results on '"Spertini, F."'

Search Results

3. Late Skin Fibrosis in Systemic Sclerosis: A Study from the EUSTAR Cohort

4. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

5. Anwendung von Biologika bei allergischen und Typ-2- entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie – ein Positionspapier von AeDA, DGAKI, GPA, ÖGAI, LGAI, ÖGP, ARIA und EAACI

6. Toxic Shock Syndrome Toxin-1, Toxic Shock, and the Immune System

9. POS0317 THE PERFORMANCE OF DIFFUSING CAPACITY FOR MONOXIDE CARBON (DLCO) AND FORCED VITAL CAPACITY (FVC) IN PREDICTING THE ONSET OF SYSTEMIC SCLEROSIS (SSc)-INTERSTITIAL LUNG DISEASE (ILD) IN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) DATABASE

11. Allergen-Immuntherapie in der aktuellen COVID-19-Pandemie : Ein Positionspapier von ARIA, EAACI, AeDA, GPA und DGAKI (Kurzversion)

12. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

13. Racial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group study

14. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B<

15. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

16. Use of biologicals in allergic and type 2 inflammatory diseases in the current COVID-19 pandemic [Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie]

17. Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study

25. Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort

26. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities

27. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study

28. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis

34. TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development

35. Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study

38. Davantage de silence

45. Results of the phase-I open-label clinical trial SAKK 06/14 assessing safety of intravesical instillation of the recombinant BCG VPM1002BC in patients with non-muscle invasive bladder cancer and previous failure to conventional BCG therapy

47. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis

48. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis

49. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis

50. Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study

Catalog

Books, media, physical & digital resources